Payment overview · 2025
General Payments
$294.36
15 reported records · 9 companies
Healthcare provider profile · identity verified
Kortney Winkleman, ARNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · PALATKA, FL · NPI 1295408482
Verified facts
What the public records show
CMS Open Payments records show Kortney Winkleman, ARNP received $294.36 in general payments during 2025 across 15 reported records.
Novartis Pharmaceuticals Corporation accounted for 25.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 25 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $75.82 | 25.8% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $38.66 | 13.1% | 2 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $38.59 | 13.1% | 3 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $28.21 | 9.6% | 1 | 2025 |
| CVRx, Inc. | Unresolved — no canonical attribution shown | $25.59 | 8.7% | 1 | 2025 |
| Ionis Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.10 | 8.2% | 1 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $23.49 | 8.0% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $20.94 | 7.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $18.96 | 6.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $294.36 | 15 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $75.82 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $38.66 | 2 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $38.59 | 3 | 2025 |
Source payment records
|
|||||
| OPSYNVI Normalized: opsynvi |
Drug | Actelion Pharmaceuticals US, Inc. | $28.21 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $28.21 | 1 | 2025 |
Source payment records
|
|||||
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $25.59 | 1 | 2025 |
Source payment records
|
|||||
| TRYNGOLZA Normalized: tryngolza |
Drug | Ionis Pharmaceuticals, Inc. | $24.10 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | Celgene Corporation | $23.49 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $21.78 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $20.94 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $18.96 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 36 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 25 supporting records · 24 recipient NPIs · example record 1184385048 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
36 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 630 | 255 |
| Lisinopril | Lisinopril | 336 | 132 |
| Atorvastatin Calcium | Atorvastatin Calcium | 301 | 131 |
| Amlodipine Besylate | Amlodipine Besylate | 288 | 117 |
| Losartan Potassium | Losartan Potassium | 275 | 107 |
| Omeprazole | Omeprazole | 249 | 123 |
| Levothyroxine Sodium | Levothyroxine Sodium | 182 | 84 |
| Metformin Hcl Er | Metformin Hcl | 175 | 75 |
| Pioglitazone Hcl | Pioglitazone Hcl | 172 | 76 |
| Fenofibrate | Fenofibrate | 169 | 68 |
| Ezetimibe | Ezetimibe | 158 | 65 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 153 | 61 |
| Gabapentin | Gabapentin | 136 | 83 |
| Meloxicam | Meloxicam | 136 | 72 |
| Metformin Hcl | Metformin Hcl | 123 | 54 |
| Metoprolol Succinate | Metoprolol Succinate | 121 | 60 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 117 | 61 |
| Tamsulosin Hcl | Tamsulosin Hcl | 109 | 56 |
| Tizanidine Hcl | Tizanidine Hcl | 105 | 46 |
| Hydrochlorothiazide | Hydrochlorothiazide | 104 | 47 |
| Pantoprazole Sodium | Pantoprazole Sodium | 99 | 45 |
| Sertraline Hcl | Sertraline Hcl | 98 | 44 |
| Metoprolol Tartrate | Metoprolol Tartrate | 95 | 47 |
| Montelukast Sodium | Montelukast Sodium | 95 | 46 |
| Trazodone Hcl | Trazodone Hcl | 95 | 50 |
| Zolpidem Tartrate | Zolpidem Tartrate | 69 | 19 |
| Prednisone | Prednisone | 68 | 59 |
| Furosemide | Furosemide | 67 | 39 |
| Doxycycline Hyclate | Doxycycline Hyclate | 64 | 59 |
| Clopidogrel | Clopidogrel Bisulfate | 63 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 58 | 25 |
| Buspirone Hcl | Buspirone Hcl | 56 | 32 |
| Carvedilol | Carvedilol | 55 | 29 |
| Famotidine | Famotidine | 53 | 28 |
| Potassium Chloride | Potassium Chloride | 53 | 31 |
| Alendronate Sodium | Alendronate Sodium | 52 | 27 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 49 | 19 |
| Simvastatin | Simvastatin | 45 | 16 |
| Bupropion Xl | Bupropion Hcl | 44 | 23 |
| Amoxicillin | Amoxicillin | 43 | 41 |
| Warfarin Sodium | Warfarin Sodium | 41 | suppressed |
| Azithromycin | Azithromycin | 37 | 37 |
| Invokana | Canagliflozin | 37 | 25 |
| Tresiba Flextouch U-100 | Insulin Degludec | 37 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 36 | 35 |
| Eliquis | Apixaban | 36 | 20 |
| Atenolol | Atenolol | 34 | 15 |
| Clonidine Hcl | Clonidine Hcl | 34 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 33 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 33 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 33 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 32 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 32 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 32 | 16 |
| Allopurinol | Allopurinol | 31 | 15 |
| Spironolactone | Spironolactone | 31 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 30 | 25 |
| Tresiba | Insulin Degludec | 28 | 17 |
| Alprazolam | Alprazolam | 27 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 25 |
| Dicyclomine Hcl | Dicyclomine Hcl | 27 | 15 |
| Meclizine Hcl | Meclizine Hcl | 27 | 20 |
| Donepezil Hcl | Donepezil Hcl | 26 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 26 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 26 | 13 |
| Sildenafil Citrate | Sildenafil Citrate | 26 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 25 |
| Fluconazole | Fluconazole | 24 | 19 |
| Valsartan | Valsartan | 24 | suppressed |
| Methylprednisolone | Methylprednisolone | 23 | 22 |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Glipizide | Glipizide | 22 | suppressed |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Acyclovir | Acyclovir | 21 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 21 | 12 |
| Finasteride | Finasteride | 21 | suppressed |
| Baclofen | Baclofen | 20 | 12 |
| Clonazepam | Clonazepam | 19 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 19 | suppressed |
| Temazepam | Temazepam | 19 | suppressed |
| Ibuprofen | Ibuprofen | 18 | 12 |
| Primidone | Primidone | 18 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Cephalexin | Cephalexin | 17 | 16 |
| Levofloxacin | Levofloxacin | 17 | 17 |
| Novolog | Insulin Aspart | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | 11 |
| Digoxin | Digoxin | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 13 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Celecoxib | Celecoxib | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Ibu | Ibuprofen | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $294.36 · 15 records | Novartis Pharmaceuticals Corporation | Barostim Neo System, ELIQUIS, ENTRESTO, FARXIGA, JARDIANCE, LEQVIO, LifeVest, OPSYNVI, TRYNGOLZA, UPTRAVI, VERQUVO | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Celgene Corporation?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error